Heart Transplantation Clinical Trial
Official title:
A Prospective Randomized Single Blind Multicenter Phase II Study of Organ Perfusion With Custodiol-N Compared With Custodiol in Heart Transplantation in Children
Verified date | April 2023 |
Source | Dr. F. Köhler Chemie GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this prospective randomized single blind multicenter phase II study is to compare organ perfusion with Custodiol-N and Custodiol in heart transplantation in children of all ages (birth to <18 years) being listed on the waiting list for heart transplantation. The main question it aims to answer is: to compare the safety of Custodiol-N in heart transplantation in children in comparison to its precursor product Custodiol. Participants will receive either a heart to be transplanted, either perfused with Custodiol-N or Custodiol to Researchers will compare the two solutions to see if the new solution Custodiol-N is safe in heart transplantation in children.
Status | Active, not recruiting |
Enrollment | 15 |
Est. completion date | December 2025 |
Est. primary completion date | April 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 24 Hours to 17 Years |
Eligibility | Inclusion Criteria: - Age from birth to less than18 years - Recipients awaiting their first transplant - Ability of the patients and/ or their legal guardians to understand character and individual consequences of the clinical trial - written informed consent of the patients and/ or their legal guardians (must be available before enrolment in the study) - Patient listed on the waiting list for heart transplantation Exclusion Criteria: - Patients who have participated within 30 days or are still participating in any other interventional studies - history of severe organic disease other than concerning the heart - history/demonstration of HIV antibodies or AIDS - multiorgan transplantation - machine-perfused organ - the explantation team is affiliated to another clinic than transplantation team - Failing Fontan patients - Patients who have been incarcerated or involuntarily institutionalized by court order or by the authorities - Pregnancy and lactation |
Country | Name | City | State |
---|---|---|---|
Germany | Deutsches Herzzentrum der Charité | Berlin | |
Germany | Universitätsklinikum Gießen (UKGM), Kinderherzzentrum, Klinikum für Kinderherzchirurgie | Gießen | |
Germany | Klinikum der Universität München (LMU), Klinik und Poliklinik für Herzchirurgie, Chirurgische Klinik | München |
Lead Sponsor | Collaborator |
---|---|
Dr. F. Köhler Chemie GmbH |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | adverse event reporting | Safety assessment | up to 3 months | |
Secondary | heart rate | vital parameters | up to day 7 after release of the aortic cross clamp | |
Secondary | blood pressure (systolic (SBP) and diastolic (DBP)) | vital parameters | up to day 7 after release of the aortic cross clamp | |
Secondary | body temperature | vital parameters | up to day 7 after release of the aortic cross clamp | |
Secondary | concentration of cardiac troponin | laboratory tests | up to day 7 after release of the aortic cross clamp | |
Secondary | concentration of creatinine kinase (CK-MB) | laboratory tests | up to day 7 after release of the aortic cross clamp | |
Secondary | (SBP (systolic blood pressure), DBP (diastolic blood pressure)) | Haemodynamics | from termination of cardiopulmonary bypass until transfer to intensive care unit | |
Secondary | Heart Rhythm (HR) | Haemodynamics | from termination of cardiopulmonary bypass until transfer to intensive care unit | |
Secondary | Pulmonary artery pressure (PAP (if available)) | Haemodynamics | from termination of cardiopulmonary bypass until transfer to intensive care unit | |
Secondary | Cerebrovascular resistance (CVR (if available)) | Haemodynamics | from termination of cardiopulmonary bypass until transfer to intensive care unit | |
Secondary | Death | survival | up to 12 months | |
Secondary | function of transplanted organ (heart) | Graft survival | up to 3 months | |
Secondary | Readmission to intensive care unit (ICU) | return to intensive care unit | up to 3 months | |
Secondary | Length of ICU stays | duration of stay in intensive care unit | up to 3 months | |
Secondary | Catecholamine requirement | (yes/no) | up to day 7 | |
Secondary | Antihypertensives intake | (yes/no) | up to 12 months | |
Secondary | Milrinone support | (yes/no) | up to day 7 | |
Secondary | Need for pacemaker therapy | (yes/no) | up to day 7 | |
Secondary | Left and right ventricular assist device (LVAD, RVAD) | Device therapy (each yes/no) | up to 3 months | |
Secondary | Extracorporeal membrane oxygenation (ECMO) | Device therapy (each yes/no) | up to 3 months | |
Secondary | Biventricular assist Device (BIVAD) or percutaneous LVAD | Device therapy (each yes/no) | up to 3 months | |
Secondary | Ejection fraction | Echocardiographic markers of function and rejection | up to day 7 | |
Secondary | enddiastolic and endsystolic ventricle | Echocardiographic markers of function and rejection | up to day 7 | |
Secondary | Cardiac arrhythmias | occurrence, severity, type | up to day 7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06035991 -
First Clinical Evaluation of Heart Transplantation With Grafts Preserved Using an Ex-vivo Extended Perfusion System
|
N/A | |
Recruiting |
NCT01927614 -
Advanced Cardiac Imaging in Cardiac Allograft Vasculopathy
|
N/A | |
Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Completed |
NCT01028599 -
Effect of Physical Training on Oxygen Uptake and Endothelial Function in Heart Transplant Recipients
|
N/A | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Terminated |
NCT00420537 -
Shift to Everolimus (RAD) Kidney Sparing Study
|
Phase 4 | |
Enrolling by invitation |
NCT03292861 -
The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT04924491 -
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children
|
Phase 1/Phase 2 | |
Recruiting |
NCT05270902 -
Haemoadsorption During Heart Transplantation
|
N/A | |
Completed |
NCT05289180 -
Brachial Right Ventricle - Endomyocardial Biopsy
|
||
Recruiting |
NCT03687723 -
Observational Study of the Clinical Use of the OCS™ Heart
|
||
Completed |
NCT01091194 -
Effect of Exercise After Heart Transplantation
|
Phase 2 | |
Withdrawn |
NCT00780637 -
Brachial Artery t-PA Release in Heart Transplant Recipients
|
N/A | |
Withdrawn |
NCT00780377 -
Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients
|
N/A | |
Terminated |
NCT00678002 -
Quality of Life in Pediatric Transplant Patients
|
||
Completed |
NCT01182571 -
Exploration of Fatigue, Uncertainty, Depression and Quality of Life in Heart Transplantation Recipients
|
N/A | |
Terminated |
NCT00121784 -
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
|
Phase 4 | |
Withdrawn |
NCT00572286 -
Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study
|
N/A | |
Completed |
NCT00123331 -
Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation
|
Phase 4 |